Gene therapy and angiogenesis in patients with coronary artery disease

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Molecular Biology

Background:

• Current treatments for severe coronary artery disease (CAD) are insufficient for all patients.
• Vascular growth factors (e.g., VEGF, FGF) can induce angiogenesis in ischemic tissues.
• Previous studies explored growth factors for CAD with mixed results.

Purpose of the Study:

• To review the efficacy of vascular growth factors in treating severe coronary artery disease.
• To evaluate the transition from early promising studies to larger, controlled trials.
• To identify future therapeutic strategies for refractory CAD.

Main Methods:

• Review of clinical trials investigating vascular growth factors (VEGF, FGF) in coronary artery disease.
• Analysis of early unblinded studies and subsequent larger double-blind placebo-controlled trials.
• Assessment of clinical outcomes and evidence of angiogenesis.

Main Results:

• Initial small studies showed clinical improvement and angiogenesis with growth factors.
• Larger, placebo-controlled trials did not confirm the high efficacy of growth factor protein or gene therapy.
• No gene-related serious adverse events were reported in conducted clinical studies.

Conclusions:

• Growth factor therapy for severe coronary artery disease has shown limited success in large trials.
• Future research may involve combination therapies, such as growth factor cocktails or gene and stem cell therapy.
• Optimizing treatment for patients with severe CAD unresponsive to current strategies remains a critical goal.